SciSparc Files International Patent for Weight Loss Therapy
Ticker: SPRC · Form: 6-K · Filed: Jul 31, 2025 · CIK: 1611746
| Field | Detail |
|---|---|
| Company | Scisparc Ltd. (SPRC) |
| Form Type | 6-K |
| Filed Date | Jul 31, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: patent-filing, collaboration, healthcare, drug-development
TL;DR
SciSparc filed a patent for a new weight loss & fatty liver drug combo with Clearmind.
AI Summary
On July 30, 2025, SciSparc Ltd. announced the filing of an international patent application for a novel combination therapy targeting weight loss and fatty liver disease, developed in collaboration with Clearmind. This patent application covers the use of their combined therapies, potentially offering new treatment options for these conditions.
Why It Matters
This patent filing could lead to new therapeutic options for weight loss and fatty liver disease, potentially impacting the healthcare market and SciSparc's future revenue streams.
Risk Assessment
Risk Level: medium — The success of a patent application and the subsequent commercialization of the therapy are subject to significant regulatory and market risks.
Key Players & Entities
- SciSparc Ltd. (company) — Registrant and collaborator
- Clearmind (company) — Collaboration partner
- July 30, 2025 (date) — Date of press release and patent filing announcement
FAQ
What is the specific nature of the novel combination therapy SciSparc and Clearmind are patenting?
The filing mentions a novel combination therapy targeting weight loss and fatty liver disease, but specific details of the therapy's components are not provided in this summary.
What is the status of the international patent application?
The filing states that an international patent application has been filed, indicating it is in the early stages of the patent process.
What are the potential therapeutic indications for this combination therapy?
The therapy is targeted at weight loss and fatty liver disease.
When was the press release regarding this patent filing issued?
The press release was issued on July 30, 2025.
What is SciSparc Ltd.'s primary business focus?
While this filing focuses on a specific patent, SciSparc Ltd. is generally involved in developing treatments for neurological and related conditions.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 31, 2025 regarding SciSparc Ltd. (SPRC).